Adults 18 to 70, any sex, with Kidney Transplant. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percent of Patients With at Least One Inquiry From a Potential Living DonorPrimary· Baseline, 12 months
Data collection form that captures potential recipient ID (i.e. study participant), date of living donor inquiry, and donor inquiry ID, will be securely obtained from each transplant center following a 12 month period from enrollment. Data will be collected electronically for all study participants through a secure, HIPAA-compliant data server (QualityNet). The percent of patients with at least one inquiry from a potential living donor among patients who receive Living ACTS will be compared to those who receive a control website with embedded educational video.
Baseline
Group
Value
95% CI
Living ACTS Website
15.63
Standard Transplant Education Procedures
15.63
12 months post-intervention
Group
Value
95% CI
Living ACTS Website
15.77
Standard Transplant Education Procedures
15.87
Knowledge and Understanding of Donation/Transplantation Assessment ScoreSecondary· Baseline, Day 1 immediately post-intervention
Scale includes 13 true/False questions, score ranges from 0 to 13, 0 Min-13 Maximum where higher scores indicate greater knowledge (i.e., participants receive 1 point for each correct answer).
Knowledge assessment score at baseline
Group
Value
95% CI
Living ACTS Website
10.00
± 1.49
Standard Transplant Education Procedures
10.18
± 1.60
Knowledge assessment score at average 12 months post-intervention
Group
Value
95% CI
Living ACTS Website
10.14
± 1.45
Standard Transplant Education Procedures
10.03
± 1.72
Motivation Scale Score to Ask a Family Member to be a Living DonorSecondary· Baseline, Day 1 immediately post-intervention
9-item scale assesses motivation to ask a family member to be a living donor. Potential responses range from 1 to 5, Possible score range from 9 to 45 with higher values indicating stronger agreement with the statement.
Motivation scale score at baseline
Group
Value
95% CI
Living ACTS Website
36.03
± 5.00
Standard Transplant Education Procedures
35.58
± 4.86
Motivation scale score at average 12 months post-intervention
Group
Value
95% CI
Living ACTS Website
37.00
± 4.93
Standard Transplant Education Procedures
36.38
± 4.98
Confidence in Initiating a Conversation About LDKTSecondary· Baseline, Day 1 immediately post-intervention
10-item behavioral skills scale measures confidence in initiating a conversation about LDKT. Potential responses range from 1 to 5, total possible score range is 10-50, with higher values indicate stronger confidence.
Behavioral skills scale score at baseline
Group
Value
95% CI
Living ACTS Website
40.38
± 7.35
Standard Transplant Education Procedures
39.45
± 6.63
Behavioral skills scale score at average 12 months post-baseline
Group
Value
95% CI
Living ACTS Website
41.98
± 6.88
Standard Transplant Education Procedures
40.46
± 6.85
Sponsor's own description
For most of the patients in the United States with end stage renal disease (ESRD), kidney transplantation represents the optimal treatment, and living donor kidney transplantation (LDKT) is preferable. Nevertheless, there are pervasive racial disparities in access to LDKT. The main outcome of this study is change in the proportion of study participants who have at least one living donor inquiry by friends/family over study period.The long-term objective is to understand the combined effect of a systems-level intervention (Transplant Referral EXchange or T-REX) and a culturally-sensitive individual-level educational intervention (web-based Living ACTS: About Choices in Transplantation and Sharing) on racial disparities in access to LDKT.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07532382 — Personalized Stories for Pediatric Kidney Recipients
· recruiting
NCT07348458 — Kidney Protective Jacket
· NA
· recruiting
NCT07333495 — A Mixed Cohort, Multicentre Exploratory Study of Non-invasive Quantitative Assessment of Renal Graft Function With Non-c
· recruiting
NCT06919003 — Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE
· Phase 2
· recruiting
NCT07205692 — Multimorbidity and Cardiovascular Risk Factors After Renal Transplant
· recruiting
Other Emory University trials
Trials by the same sponsor.
NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study
· NA
· withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait
· NA
· not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose
· NA
· not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I
· Phase 2
· recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 24 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03819686.